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Co-expressionsBoth Ki67 and HER2 are key prognostic molecules for invasive breast cancer (BC), but the individual relative im-
pacts on prognosis of thesemolecules are not known. This studywas aimed at establishing a quantum dot (QD)-
based double-color in-situ quantitative imaging technique to study the co-expressions of Ki67 andHER2, and de-
lineate the individual impacts of these molecules on prognosis. The QD-based ﬂuorescent immunostaining tech-
nique could simultaneously image the co-expressions of Ki67 andHER2 in BC specimens, with the former stained
as clear red ﬂuorescence in cancer cell nucleus, and the latter as bright green ﬂuorescence on cancer cell mem-
brane. Both Ki67 and HER2 expressions were signiﬁcantly correlated with 8-year disease free survival (8-DFS)
(P b 0.05). However, the twomolecules had different weights in terms of negative impacts on clinical prognosis.
The median 8-DFS was statistically signiﬁcantly shorter in High-Ki67 High-HER2 subgroup than Low-Ki67 High-
HER2 subgroup (11.7 vs. 60.1 months, P b 0.05), shorter in High-Ki67 Low-HER2 subgroup than Low-Ki67 Low-
HER2 subgroup (16.4 vs. 96.0 months, P b 0.01), shorter in High-Ki67 High-HER2 subgroup than Low-Ki67 Low-
HER2 subgroup (11.7 vs. 96.0 months, P b 0.01), but there were no statistically signiﬁcant differences in median
8-DFS between High-Ki67 Low-HER2 subgroup and High-Ki67 High-HER2 subgroup (11.7 vs. 16.4 months, P=
0.586). The hazard ratio (HR) of Ki67 negative impact on 8-DFS was about 3 fold of that of HER2 (HR 4.493 vs.
1.481). This study demonstrated that QD-based ﬂuorescent imaging technique could help the quantitative
study on the co-expressions of Ki67 and HER2 in BC, and Ki67 has a greater negative impact on BC prognosis
than HER2.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Breast cancer (BC) is themost commonmalignant tumor forwomen
in both developed and developing countries (Torre et al., 2015) particu-
larly in China, where BC ranks the secondmost common cancer for both
males and females combined, according to the latest National Cancer
Registry (Chen et al., 2015). Although the BC survival has been steadily
increasing globally (Allemani et al., 2015) with a 5-year survival rate
reaching well above 85% in 17-developed countries, the 5-year survival
in China is only about 73% (Zeng et al., 2015).
Curative-surgery basedmulti-disciplinary treatment is currently the
standard therapy for BC. Under this treatment strategy, key information
on tumor biology plays an important role in treatment decisionmaking.
In the era of molecular medicine, many important BC molecules have
been identiﬁed and validated. Among the currently available and wellZhongnan Hospital of Wuhan
cal Behaviors & Hubei Cancer
, China.
. This is an open access article undervalidated molecules are Ki67 and human epidermal growth factor
receptor-2 (HER2).
Ki67was identiﬁed as a nuclear antigen associatedwith cell prolifer-
ation by Gerdes et al. (1983) in the early 1980s. A detailed cell cycle
analysis revealed that the antigen was expressed in all phases of the
cell cycle except for theG0 phase (Gerdes et al., 1984, 1991).Many stud-
ies have demonstrated the important role of proliferation biomarkers in
BC and most of them supported that Ki67 expression levels were nega-
tively correlated with BC prognosis (Inwald et al., 2013; Kontzoglou
et al., 2013; Reyal et al., 2013; Yang et al., 2011; Yerushalmi et al., 2010).
HER2 is a 185 kDa transmembrane protein encoded by oncogene
HER2/neu or c-erbB-2 (Slamon et al., 1989). HER2 is a key member of
the epidermal growth factor receptor family involved in tumor prolifer-
ation, angiogenesis, drug resistance and metastasis (Allison, 2010; Ross
et al., 2009;Wolff et al., 2007). HER2 is overexpressed in approximately
25–30% of invasive BC, indicating more aggressive biological behaviors
and special treatment requirements (Benson et al., 2009; Freudenberg
et al., 2009; Goldhirsch et al., 2009; Wolff et al., 2007). Currently, the
molecular-targeted therapy for HER2 has a tremendous impact on BC
treatment (Hudis, 2007; Liberato et al., 2007).the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Table 1
Major clinic-pathological features of 33 patients.
Items Value %
Age (years)
≤50 23 (69.7)
N50 10 (30.3)
T stage
T1 (diameter ≤ 2 cm) 6 (18.2)
T2 (2 cm b diameter ≤ 5 cm) 24 (72.7)
T3 (diameter N 5 cm) 3 (9.1)
N stage
N0 13 (39.4)
N1 7 (21.2)
N2 10 (30.3)
N3 3 (9.1)
Histological grade
I 10 (30.3)
II 17 (51.5)
III 6 (18.2)
M stage
M0 33 (100)
M1 0
Pathological types
Invasive ducal carcinoma 32 (97.0)
Medullary carcinoma 1 (3.0)
Surgical procedures
Modiﬁed radical mastectomy 28 (84.8)
Simple mastectomy 5 (15.2)
Chemotherapy
Anthracycline-based regimens 19 (57.6)
Taxane-based regimens 10 (30.3)
CMF 4 (12.1)
Radiotherapy
Yes 13 (39.4)
No 20 (60.6)
134 Q.-M. Xiang et al. / Experimental and Molecular Pathology 99 (2015) 133–138Although the Ki67 and HER2 have been extensively studied, both as
prognostic markers and molecular treatment targets, the relative im-
pacts on disease course in the real-life situation have been unclear,
because currently there have been few studies to simultaneously inves-
tigate the quantitative expressions of thesemolecules and take themul-
tivariate approaches to delineate the weighted individual impacts of
these molecules on prognosis. This is largely due to the situation that
current techniques mostly take univariate approaches, i.e. studying
one molecule at one time and piece-together the information to assist
treatment decision making and prognosis prediction (Peng et al.,
2010; Wang et al., 2015). Therefore, there is an acute clinical need for
new techniques to simultaneously and quantitatively study the expres-
sions of several keymolecules. And information obtained from such im-
proved technologies could help us better understand BC tumor biology
and formulate more practical treatment algorithm.
Quantum dot (QD) is nanoparticle with unique size and surface ef-
fects which shows excellent optical properties, such as high ﬂuores-
cence intensity, strong resistance to photobleaching and chemical
degradation, size-tunable emission wavelength and simultaneous mul-
tiple ﬂuorescent colors under single source excitation (Chen et al., 2012;
Wang et al., 2015). The latter property is particularly useful inmolecular
pathology to simultaneously study multi-makers (Chen et al., 2009,
2010; Yuan et al., 2015). Therefore, this study aimed at establishing a
QD-based double ﬂuorescent imaging to quantitatively and simulta-
neously study the co-expressions of Ki67 and HER2, and explore the in-
dividual impacts of these two molecules on invasive BC.
2. Materials and methods
2.1. Patients and materials
Formalin-ﬁxed parafﬁn-embedded specimens from 33 invasive BC
patients with complete clinic-pathological and follow-up information
were selected from our prospectively established cancer database,
which has been the source of our recent clinical studies on BC (Wang
et al., 2013; Yuan et al., 2015). Major pathological parameters were all
available, including the tumor size, location and number, lymph node
(LN) status, histological grade, hormone receptor status and informa-
tion on key molecules. As this study was focused on HER2 and Ki67,
these 33 cases were chosen primarily based on the following criteria:
(1) invasive BC with curative surgery, complete standardized chemo/
radiotherapy, endocrine therapy and/or molecular targeting therapy,
as deemed necessary according to the clinical guidelines; (2) deﬁnite
information on HER2 score 2+ or 3+, as determined by conventional
immunohistochemistry (IHC), according to the pathological guidelines
(Hammond et al., 2010); (3) deﬁnite information on Ki67 indexwas de-
termined by IHC according to the recommendations from the Interna-
tional Ki67 in Breast Cancer Working Group (Dowsett et al., 2011);
and (4) complete information on 8-year disease free survivals (8-DFS)
was available. DFS is deﬁned as the time interval from the BC
surgery to the ﬁrst evidence of tumor recurrence (local, regional, or
distant). In this study, the median 8-DFS was 62.9 months (range 7.0
to 96.0months). The study protocolwas approved from the Ethics Com-
mittee of Zhongnan Hospital of Wuhan University, and written in-
formed consent was obtained from the patients before surgery to use
the resected specimens for scientiﬁc researches, in addition to routine
pathological diagnosis. Detailed information on these 33 cases was
summarized in Table 1.
2.2. QD-based double-color ﬂuorescent imaging
QD-based ﬂuorescent multiple immunostaining technique has been
established at our cancer center with detailed procedures reported pre-
viously (Hu et al., 2014; Peng et al., 2011; Sun et al., 2014) and briefed as
the following (Fig. 1A2). Parafﬁn slides heating → de-parafﬁnizing →
hydration→ antigen retrieval in citrate buffer→ blocking with BSA→primary antibodies for Ki67 and HER2 at 4 °C overnight → staining
with QD-525 and QD-655 simultaneously→washing→ image acquisi-
tion and quantiﬁcation.
For ﬂuorescent imaging of Ki67, the primary antibody was rabbit
anti-human against Ki67 monoclonal antibody (Clone: SP6; dilution:
1:100). SP6 monoclonal antibody has been conﬁrmed to have equal
speciﬁcity with MIB6 (Dowsett et al., 2011; Voros et al., 2013), but
slightly better performance for quantitative image analysis (Zabaglo
et al., 2010). The secondary antibody was QD-655-conjugated mouse
F(ab′)2 anti-rabbit IgG (dilution: 1:200, Life Technologies, USA, emitting
red ﬂuorescence).
For ﬂuorescent imaging of HER2, the primary antibody was mouse
anti-human HER2 polyclonal antibody (Clone: CB11; dilution: 1:100,
FuzhouMaxim Biotech Co., Ltd. Fuzhou, China). The secondary antibody
was QD-525 conjugated goat anti-mouse IgG (dilution: 1:50, Life
Technologies, USA, emitting green ﬂuorescence), which could directly
demonstrate the ﬂuorescent green signal of HER2 on cell membrane.
2.3. Image acquisition, quantiﬁcation and analysis
QD ﬂuorescent information on Ki67 and HER2 of BCwas acquired by
CRi Nuance multispectral imaging systems (Cambridge Research & In-
strumentation, Inc., Woburn, MA, USA) under an ultraviolet light
(330–385 nm) at 200× magniﬁcations. For each QD staining section, a
total of 5 spectral cubes containing the complete spectral information
at 10-nm wavelength intervals from 450 nm to 700 nm were random-
ized obtained from different areas of the section by CRi Nuance multi-
spectral imaging systems under the same exposure time (600 ms).
After image acquisition, the software package within CRi Nuance
multispectral imaging system was applied to quantify the QD ﬂuores-
cence information on Ki67 andHER2 in each cube image, whichwas de-
tailed described in our previous study, and briefed as the following:
(1) selection of targets of Ki67, HER2 and background with different
spectra; (2) image unmixing of targets and elimination of background
Fig. 1. The design and major technical procedures of this study. Tumor tissue section slides were prepared from 33 selected patients with invasive BC (A1). Ki67 and HER2 were stained
with QDmultiple imagingmethod, Ki67 signal as bright red ﬂuorescence andHER2 signal as green ﬂuorescence (A2). Images acquisition, unmixing and quantiﬁcation by CRi Nuance soft-
ware (B1→ B3). Ki67 and HER2 values were analyzed by X-tile software (C1), divided into two grades (C2), and analyzed by Kaplan–Meier method (C3).
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ﬁnal quantitative results of Ki67 and HER2 for each patientwere the av-
erage values of Ki67 and HER2 for the 5 cube images.
Once the Ki67 and HER2 results were obtained, the X-tile software,
developed by Camp et al. in 2004 to ﬁnd optimal cut-point of bio-
markers based on the prognosis (Camp et al., 2004), was applied to au-
tomatically judge the cut-off points of Ki67 andHER2, and divided them
into low and high categories according their values, respectively.
2.4. Statistical analysis
The statistical analysis was performedwith SPSS 19.0 software (SPSS
Inc., Chicago, IL, USA). The primary endpoint, 8-DFS of BC patients was
calculated by the Kaplan–Meier (KM) survival analysis and analyzedby the Log-rank test. Multivariate analysis on potential parameters
was performed by Cox proportional regression model method. Two-
sided P b 0.05 was considered as statistically signiﬁcant.3. Results
3.1. QD-based double-color ﬂuorescent images for Ki67 and HER2
Ki67 was expressed in cancer cell nucleus as clear red ﬂuorescence,
HER2 on cancer cell membrane as bright green ﬂuorescence, and the
sharp image color and spectrum contrast made it easy for signal separa-
tion and quantiﬁcation. The typical QD-based double-color images and
unmixed “single-color” images were presented in Fig. 2.
Fig. 2.QD-baseddouble-color in-situﬂuorescent imaging for Ki67 andHER2 inBC. QD-baseddouble-color images for Ki67 andHER2, Ki67was expressed as clear redﬂuorescence, HER2 as
bright green ﬂuorescence (A); the spectral images of Ki67 andHER2 co-expressionswere obtained by CRi Nuancemultispectral imaging system, which could unmix the images into single
color images (B); the single red ﬂuorescent image representing Ki67 at the emitting wavelength of 655 nm (C); and the single green ﬂuorescent representing HER2 at the emitting wave-
length of 525 nm (D). 200×, scale bar = 50 μm.
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Nuancemultispectral imaging analysis software was used to quanti-
fy the expressions of both Ki67 and HER2. Among the 33 specimens, the
Ki67 quantiﬁcation ranged from 129,190.3 to 5,314,205.6 (median
1,674,173.7), and the HER2 quantiﬁcation ranged from 36,790.3 to
18,892,843.6 (median 3,969,935.7).
According to the results of X-tile software, the optimal cut-off value
of Ki67 was 3,684,227.0, and patients were divided into two groups, i.e.
High Ki67 expression (n = 5) and Low Ki67 expression (n = 28)
groups; the cut-off value of HER2was 2,114,651.0, and patientswere di-
vided into High HER2 expression (n = 14) and Low HER2 expression
groups (n = 19). The median 8-DFS in patients between High and
Low Ki67 expression groups had statistically signiﬁcant difference
(11.7 months [95% CI: 7.0–26.6] vs. 89.7 months [95% CI: 7.4–96.0],
P b 0.01, Fig. 3A), but there were no signiﬁcant differences betweenFig. 3. The correlation between Ki67 and HER2 expressions and 8-DFS. Both Ki67 and HER2 ex
expressions on 8-DFS. I: Low-Ki67 Low-HER2, II: Low-Ki67 High-HER2, III: High-Ki67 Low-HERHigh and Low HER2 expression groups (36.3 months [95% CI: 7.4–
96.0] vs. 93.0 months [95% CI: 7.0–96.0], P= 0.09, Fig. 3B).
3.3. Co-expressions of Ki67 and HER2 in terms of 8-DFS
In real clinical practice, BC key molecules such as Ki67 and HER2 are
present together in the tumor. Therefore, it is essential to study the im-
pact of Ki67 and HER2 co-expressions by a combined analysis. All possi-
ble Ki67 andHER2 expression variationswere divided into 4 subgroups:
High-Ki67 High-HER2 subgroup, Low-Ki67 High-HER2 subgroup, High-
Ki67 Low-HER2 subgroup, and Low-Ki67 Low HER2 subgroup.
The median 8-DFS was statistically signiﬁcantly shorter in High-Ki67
High-HER2 subgroup than Low-Ki67 High-HER2 subgroup (11.7months
[95% CI: 11.0–26.6] vs. 60.1 months [95% CI: 7.4–96.0], P b 0.05), shorter
in High-Ki67 Low-HER2 subgroup than Low-Ki67 Low-HER2 subgroup
(16.4 months [95% CI: 6.97–25.67] vs. 96.0 months [95% CI: 16.0–96.0],pressions were negatively correlated with 8-DFS (A, B). The impacts of Ki67 and HER2 co-
2, and IV: High-Ki67 High-HER2 (C).
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HER2 subgroup (11.7 months [95% CI: 11.0–26.6] vs. 96.0 months
[95% CI: 16.0–96.0], P b 0.01); but there were no statistically signiﬁcant
differences in 8-DFS between High-Ki67 Low-HER2 subgroup and
High-Ki67 High-HER2 subgroup (11.7 months [95% CI: 11.0–26.6] vs.
16.4 months [95% CI: 6.97–25.67], P= 0.586) (Table 2, Fig. 3C).
3.4. Weighted analysis of the impacts of Ki67 and HER2 on 8-DFS
From the above analysis, it is evident that Ki67 has a greater negative
impact on BC prognosis than HER2. Therefore, it is necessary to conduct
multivariate analysis to delineate the relative weighted impacts of Ki67
andHER2 on disease prognosis. The hazard ratio (HR) of Ki67was 4.493
[95% CI: 1.207–16.726], and the HR of HER2 was 1.481 [95% CI: 0.473–
4.643]. The negative impact of Ki67 on BC prognosis is about 3 fold of
that of HER2 (4.493/1.481).
4. Discussion
In this study, QD-based double-color ﬂuorescent imaging technique
was ﬁrst used to quantitatively and simultaneously detect the expres-
sions of Ki67 and HER2 in BC, and the sharp image color and spectrum
contrast made it easy for signal separation and quantiﬁcation.
BC has a highly variable prognosis for an individual patient. Increas-
ing attention is being paid to themolecular characteristics of the tumor.
ER, PR and HER2 are now well established as predictive factors for
prognosis and treatment response. Although the investigators of
International Ki67 in Breast Cancer Working Group recognized poor
agreement on the precise clinical use of Ki67 and the substantial hetero-
geneity and variable levels of validity in methods of assessment. Ki67 is
also frequentlymeasured, both as a staticmarker of proliferative activity
and by making multiple measurements during treatment, as a possible
dynamic intermediate marker of treatment efﬁciency. Many studies
have demonstrated the prognostic value of Ki67 in BC (Kontzoglou
et al., 2013; Yerushalmi et al., 2010). In order to evaluate the routine
use and value of Ki-67 as a prognostic marker, the results of a large
population-based cohort of a cancer registry (Inwald et al., 2013) sup-
ported that Ki67 expression is an independent prognostic parameter
for DFS and overall survival (OS). Among our previous works, Yang
et al. (2011) investigated the prognostic value of Ki-67 expression
for 5-year RFS of 134 patients with invasive BC and found that
high Ki-67 expression was a poor prognostic factor of BC patients; Sun
et al. (2014) considered that the Ki67 score was an independent
prognosticator in the HER2-positive (non-luminal) breast cancer pa-
tients. In accordance with their results, this study found that the 8-DFS
in patients between High and Low Ki67 expression groups had statisti-
cally signiﬁcant differences (11.7 vs 89.7 months, P b 0.01), which indi-
cated that higher Ki67 expression was associated with higher
recurrence risk.
HER2 is a major determinant of BC molecular subtype. It has been
well recognized that HER2 level in BC is closely related to themalignant
biologic behaviors of the tumor, including invasion and metastasis. In
this study, the 8-DFS is shorter in High HER2 expression group than
Low HER2 expression group, but the difference only approached theTable 2
Prognostic analysis of co-expressions of Ki67 and HER2 in 8-DFS.
Ki67 and HER2 Low-Ki67 Low-HER2 Low-Ki67 High-H
χ2 P χ2
Low-Ki67 Low-HER2 – – 3.439
Low-Ki67 High-HER2 3.439 0.064 –
High-Ki67 Low-HER2 10.671 0.001 4.417
High-Ki67 Low-HER2 14.504 0.000 4.716
The bold P value is statistically signiﬁcance (P b 0.05).border of achieving statistical signiﬁcance. This is not completely incon-
sistent with earlier statements, because the number of specimens is
small and all specimens presented positive HER2 expression (IHC 2+
and 3+).
Although both Ki67 andHER2 expressionswere inversely correlated
with BCprognosis, the detailed relationship between Ki67 andHER2 ex-
pressions remains unclear and requires further investigation. QD-based
double-color ﬂuorescent imaging technique could quantitatively and si-
multaneously in-situ detect the expressions of Ki67 andHER2 in BC, and
assess the prognostic values of Ki67 and HER2 co-expressions. The me-
dian 8-DFS was statistically signiﬁcantly shorter in High-Ki67 High-
HER2 subgroup than Low-Ki67 High-HER2 subgroup (11.7 vs. 60.1
months, P b 0.05), shorter in High-Ki67 Low-HER2 subgroup than
Low-Ki67 Low-HER2 subgroup, indicating that Ki67 was associated
with worse prognosis regardless of HER2, and in the case of Low HER2
expression, Ki67 has an independent prognosis. The differences in 8-
DFS between Low-Ki67 High-HER2 subgroup and Low-Ki67 Low-
HER2 subgroup only did not reach statistical signiﬁcance (P =
0.064), and there were no signiﬁcant differences in 8-DFS between
High-Ki67 High-HER2 subgroup and High-Ki67 Low-HER2 subgroup
(P = 0.586), suggesting that HER2 itself may have no independent
impact on 8-DFS.
The above results showed that both Ki67 and HER2 were poor prog-
nostic indicators in BC, and Ki67 has a greater negative impact on BC
prognosis than HER2. Therefore, a Coxmultivariate proportional hazard
regression model analysis was conducted to quantify the weighted
prognosis of Ki67 and HER2 expressions and revealed that the negative
impact of Ki67 on BC prognosis is about 3 fold of that of HER2 (4.493/
1.481). The reports on relationship between Ki67 and HER2 are scarce.
Jerjees et al. (2014) compared Ki67 labeling index (Ki67-LI) and
HER2-expression to assess their impacts on biological behavior and
prognosis of luminal-BC, and found that both Ki67-LI andHER2were as-
sociated with high proliferation and poor prognosis in ER-positive BC.
But in the subgroup analysis, they found that within high Ki67-LI ex-
pression, HER2 positivity was associated with poor outcome, while
within HER2-positive subgroup, Ki67-LI showed no signiﬁcant associa-
tionwith outcome (Jerjees et al., 2014). Our results are just the opposite,
it is possible that the two studies included heterogeneous groups of pa-
tients who were treated and followed in various ways, and the assays
for Ki67 and HER2 were performed with different methods, and cutoffs
to designate “positive” and “negative” expressions differed. Another
most possible reason was that the populations they selected were ER-
positive BC, and there was an interaction between ER and HER2 path-
way (Osborne et al., 2003), and the interaction led to therapy resistance
and poor prognosis in BC. Interestingly, in their study this is evident that
within HER2-negative tumors, Ki67-LI was associated with shorter sur-
vival (Jerjees et al., 2014).
While this study has some limitations. First, it was a retrospective
study using a non-randomized database. Second, it included only
33 BC specimens, leading to the possibility of sample selection bias.
Third, the study evaluated the relationship between Ki67 and HER2
expressions and patient prognosis by 8-DFS rather than OS, as DFS
sometimes could not linearly correlate with OS. Therefore, the
weighted prognosis of Ki67 and HER2 may need further study toER2 High-Ki67 Low-HER2 High-Ki67 High-HER2
P χ2 P χ2 P
0.064 10.671 0.001 14.504 0.000
– 4.417 0.036 4.716 0.030
0.036 – – 0.297 0.586
0.030 0.297 0.586 – –
138 Q.-M. Xiang et al. / Experimental and Molecular Pathology 99 (2015) 133–138quantify and validate basing on larger sample size and much more ef-
ﬁcacy endpoints.
5. Conclusion
QD-based ﬂuorescent imaging technique could help the quantitative
study on the co-expressions of Ki67 and HER2 in BC, and the negative
impact of Ki67 on BC prognosis is about 3 fold of that of HER2.
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